Please assess the completion status of the following clinical trial:

Trial Title: Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Clinical stage I-III disease~* Measurable disease defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm with spiral CT scan~* HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization~* No known brain metastases~* Hormone receptor status unspecified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Male or female~* Life expectancy \> 12 weeks~* ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%~* WBC ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500 mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* LVEF ≥ 50% as measured by echocardiogram or MUGA scan~* No other malignancy within the past year~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to swallow and retain oral medication~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib~* No ongoing or active infection~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~* No psychiatric illness or social situation that would preclude study compliance~* No other uncontrolled illness~* No gastrointestinal (GI) tract disease that would preclude ability to take oral medication~* No malabsorption syndrome~* No requirement for IV alimentation~* No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, immunotherapy, radiotherapy, or hormonal therapy for breast cancer~* No prior treatment with epidermal growth factor receptor targeting therapies~* No prior surgical procedures affecting absorption~* No prior surgery for breast cancer~* At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following:~  * Dexamethasone or dexamethasone equivalent dose ≥ 1.5 mg/day, including any of the following:~    * Cortisone (≥ 50 mg/day)~   * Hydrocortisone (≥ 40 mg/day)~   * Prednisone (≥ 10 mg/day)~   * Methylprednisolone (≥ 8 mg/day)~ * Phenytoin~ * Carbamazepine~ * Phenobarbital~ * Efavirenz~ * Nevirapine~ * Rifampin~ * Rifabutin~ * Rifapentine~ * Hypericum perforatum (St. John's wort)~ * Modafinil~* At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:~  * Clarithromycin~ * Erythromycin~ * Troleandomycin~ * Delavirdine~ * Ritonavir~ * Indinavir~ * Saquinavir~ * Nelfinavir~ * Amprenavir~ * Lopinavir~ * Itraconazole~ * Ketoconazole~ * Voriconazole~ * Fluconazole (doses up to 150 mg/day are permitted)~ * Nefazodone~ * Fluvoxamine~ * Verapamil~ * Diltiazem~ * Cimetidine~ * Aprepitant~ * Grapefruit or its juice~* At least 6 months since prior and no concurrent amiodarone~* At least 2 days since prior and no concurrent gastric pH modifiers\*, including any of the following:~  * Cimetidine~ * Ranitidine~ * Nizatidine~ * Famotidine~ * Omeprazole~ * Esomeprazole~ * Rabeprazole~ * Pantoprazole~ * Lansoprazole~* NOTE: \*Antacids are allowed within 1 hour before and after administration of study drug~* No other concurrent investigational agents~* No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy~* No concurrent herbal (alternative) medicines~* No concurrent combination antiretroviral therapy for HIV-positive patients~* Concurrent bisphosphonates allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).